ECCO 2022

Is the continuation of combination therapy the key to success in CD?

Light at the end of the Pouchitis track

The potential of histology in Crohn´s disease and how AI will contribute

Combined endpoints as new therapy goals

Combination trials open a new door in IBD treatment

Microbiota manipulation: Still a lot to learn

Ustekinumab for fistulizing disease

Combination of biologics

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

Is stopping of therapy an option in CD?

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

Is the speedity of the steroid tapering important during initiation of infliximab?

A new opportunity for proactive TDM disease control

The first combination therapy trial

When to withdraw therapy in crohn's disease?

Combination with different classes of drugs in moderate to severe UC

Proactive TDM

The interleukin-17 conundrum

How to deescalate treatment in CD?

Filgotinib for fistulizing disease

Will we improve the management of IBD by combining biologics?

FMT in UC - still far away from the success story

SPARE study in ECCO 2022

Combination of biologics - finally arrived in IBD!?

FMT is not a promising option for UC patients

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

A negative control trial for FMT in UC

Ist der Therapiestopp eine Option in CD?

מחקר SPARE ב ECCO 2022

Il primo trial di terapia biologica di combinazione

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Das Interleukin-17 Rätsel

Combinazione di biologici

Una nuova opportunità per i TDM nel controllo proattivo di malattia

FMT ist kein vielversprechender Ansatz für UC-Patienten

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Un essai négatif sur la transplantation de microbiote dans la RCH

Kombination von Biologika - endlich bei IBD angekommen!?

Which IBD patients have a higher risk of safety concerns?

Inflammatory bowel disease and cancer risk

COVID-19: still a moving target!

Is combination therapy safe?

Can we translate rheumatoid arthritis to ulcerative colitis?

Breastmilk is tuning IBD risk

A touch of the near future in IBD treatment

The heart is apparently safe with continuous Ozanimod treatment

Uno sguardo al prossimo futuro nel trattamento delle IBD

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Muttermilch beeinflusst das IBD-Risiko

The race is on IL-23 – exciting data for CD and UC

Mucosal healing: Will efficacy data translate into real world?

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

Efficacy update on JAKis

Vedolizumab: promising data for pouchitis and IBD in children

Vedolizumab is effective in chronic pouchitis after IPAA for UC

New opportunity in pouchitis treatment

Great news on pouchitis treatment - vedolizumab effective

JAK inhibition

New ways of treatment

Selective IL-23 blockade

Anti-IL-23 - a turning point?

Upadacitinib - will it be the game changer in UC?

Guselkumab as maintenace treatment in Crohn's Disease

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

JAK-Inhibition

Upadacitinib - nowy lek, duże nadzieje

Selektive IL-23 Blockade

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

Nuevos caminos en el tratamiento

Una nuova opportunità nel trattamemto della pouchite

Guselkumab come terapia di mantenimento

Anti-IL-23 - eine Zeitenwende?

Histological findings in mirikizumab treatment

Natural history of anal ulcerations in pediatric-onset CD

New therapeutic goals in UC

Patient relevant outcomes also show efficacy of upadacitinib in UC

New therapy goals: urgency and disease clearance

Disease control is possible!

New goals for IBD

Urgency und Disease Clearance

Nuevas objetivos en las EII

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Disease Control ist möglich!

COVID-19 in patients with IBD stratified acc. to therapy

The efficacy of COVID-19 vaccines in IBD - what's new?

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

Point of Care Testing / AI / Telemedicine

Ultrasound as a predictor of treatment response

Ultraschall als Prädiktor des Therapieansprechens

Digitale Tools, KI und Telemedizin

Spanish women leading contribution to ECCO 2022

ECCO guidelines on pregnancy

ECCO Richtlijnen zwangerschap

Las mujeres lideran la contribución española a la ECCO 2022